Exelixis
EXEL
58.44
+0.11
+0.19%
Exelixis
US · EXEL
#1156 by market cap
Listed 1970
58.44
+0.11
+0.19%
Live - 5344 symbols - heartbeat 58s ago
· 2026-10-08 08:26
Pre-market
59.78
+2.29%
After-hours
58.44
0.00%
Overnight
58.44
0.00%
- Market cap
- 14.48B
- P/E (TTM)i
- 18.38
- P/Bi
- 7.85
- EPSi
- 2.78
- Div yieldi
- 0.00%
- 52W posi
- 90%
Reader sentiment
Are you bullish or bearish on EXEL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 14.97, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +6.98% YoY
Margins
- Gross margin
- 96.39%
- Operating margin
- 38.48%
- Net margin
- 33.73%
Key ratios & quality
- PEG ratioi
- 0.29
- Altman Z-Scorei
- 14.97
PEG uses trailing P/E against the 3-year net income growth rate (62.53%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 853.83M | 967.78M | 987.54M | 1.43B | 1.61B | 1.83B | 2.17B | 2.32B |
| Gross profit | 827.48M | 934.68M | 951.27M | 1.38B | 1.55B | 1.76B | 2.09B | 2.24B |
| Selling & admin expenses | 206.37M | 228.24M | 293.36M | 401.72M | 459.86M | 542.71M | 492.13M | 518.73M |
| Research & development | 182.26M | 336.96M | 547.85M | 693.72M | 891.81M | 1.04B | 910.41M | 825.00M |
| Operating profit | 438.86M | 369.47M | 110.06M | 286.67M | 201.48M | 170.89M | 689.95M | 892.70M |
| Pretax profit | 452.09M | 398.11M | 130.84M | 294.15M | 234.35M | 257.52M | 681.64M | 941.21M |
| Tax | -237.98M | 77.10M | 19.06M | 63.09M | 52.07M | 49.76M | 160.37M | 158.64M |
| Net profit | 690.07M | 321.01M | 111.78M | 231.06M | 182.28M | 207.77M | 521.27M | 782.57M |
| Basic EPS | 2 | 1 | 0 | 1 | 1 | 1 | 2 | 3 |
| Diluted EPS | 2.21 | 1.02 | 0.35 | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 555.45M | 568.26M | 597.76M | 598.66M | 610.81M | 628.69M |
| Gross profit | 536.28M | 548.79M | 579.18M | 572.18M | 590.86M | 608.03M |
| Selling & admin expenses | 137.18M | 134.86M | 123.66M | 123.02M | 139.60M | 147.63M |
| Research & development | 212.23M | 200.36M | 199.16M | 213.25M | 199.92M | 211.99M |
| Operating profit | 186.86M | 213.58M | 256.36M | 235.91M | 251.34M | 248.41M |
| Pretax profit | 205.69M | 230.42M | 252.41M | 252.69M | 267.69M | 262.68M |
| Tax | 46.07M | 45.57M | 58.84M | 8.16M | 57.22M | 50.63M |
| Net profit | 159.62M | 184.85M | 193.58M | 244.53M | 210.47M | 212.05M |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.55 | 0.65 | 0.69 | 0.88 | 0.79 | 0.82 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 897.02M | 1.01B | 1.45B | 1.83B | 1.62B | 1.32B | 1.47B | 1.44B |
| Cash & ST investments | 693.33M | 852.24M | 1.21B | 1.47B | 1.31B | 995.30M | 1.11B | 1.06B |
| Inventory | 9.84M | 12.89M | 20.97M | 27.49M | 33.30M | 17.32M | 22.39M | 21.69M |
| Total assets | 1.42B | 1.89B | 2.14B | 2.62B | 3.07B | 2.94B | 2.95B | 2.84B |
| Total current liabilities | 105.47M | 142.75M | 204.66M | 337.59M | 324.36M | 394.28M | 403.77M | 405.64M |
| Short-term debt | 2.74M | -- | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 134,833,000.00 | 199,700,000.00 | 258,220,000.00 | 405,624,000.00 | 583,062,000.00 | 678,445,000.00 | 703,487,000.00 | 683,104,000.00 |
| Total equity | 1.29B | 1.69B | 1.88B | 2.21B | 2.49B | 2.26B | 2.24B | 2.16B |
| Retained earnings | -880.36M | -559.35M | -447.57M | -216.51M | -34.23M | -173.35M | -98.65M | -76.83M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.40B | 1.18B | 1.40B | 1.44B | 1.21B | 1.25B |
| Cash & ST investments | 1.03B | 791.10M | 988.54M | 1.06B | 777.21M | 839.39M |
| Inventory | 24.85M | 23.48M | 27.40M | 21.69M | 26.61M | 28.73M |
| Total assets | 2.84B | 2.68B | 2.82B | 2.84B | 2.59B | 2.49B |
| Total current liabilities | 399.10M | 336.11M | 373.78M | 405.64M | 370.98M | 361.93M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 706,223,000.00 | 644,545,000.00 | 662,847,000.00 | 683,104,000.00 | 657,845,000.00 | 650,472,000.00 |
| Total equity | 2.13B | 2.03B | 2.16B | 2.16B | 1.94B | 1.84B |
| Retained earnings | -163.29M | -219.54M | -106.06M | -76.83M | -215.79M | -262.53M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 415.72M | 526.96M | 208.98M | 400.80M | 362.61M | 333.32M | 699.97M | 884.27M |
| Depreciation & amortization | 4.92M | 8.35M | 9.14M | 13.63M | 20.88M | 25.72M | 28.80M | 29.06M |
| Free cash flow | 382.42M | 514.12M | 178.64M | 336.58M | 224.16M | 170.36M | 633.79M | 844.34M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | 0 | -550.38M | -652.03M | -947.51M |
| Ending cash balance | 315.88M | 268.14M | 320.77M | 663.89M | 502.68M | 262.99M | 217.37M | 482.49M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 211.44M | 48.99M | 290.32M | 333.52M | 251.85M | 307.74M |
| Depreciation & amortization | 7.35M | 7.34M | 7.42M | 6.95M | 6.95M | 6.98M |
| Free cash flow | 188.99M | 45.41M | 283.59M | 326.36M | 249.81M | 298.43M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -283.93M | -301.92M | -104.04M | -257.62M | -430.35M | -322.97M |
| Ending cash balance | 183.75M | 164.43M | 376.30M | 482.49M | 226.15M | 281.45M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 87.77 | 21.59 | 6.27 | 11.30 | 7.76 | 8.74 | 23.13 | 35.53 |
| ROA %i | 66.43 | 19.41 | 5.56 | 9.72 | 6.41 | 6.91 | 17.70 | 27.02 |
| ROIC %i | 85.26 | 19.64 | 5.18 | 10.74 | 6.34 | 5.37 | 18.91 | 30.40 |
| 5-year avg ROE %i | -- | -- | -- | 41.83 | 26.94 | 11.13 | 11.44 | 17.29 |
| EBIT margin %i | 52.95 | 41.14 | 11.14 | 19.98 | 12.51 | 9.34 | 31.81 | 38.48 |
| FCF / sales %i | 44.79 | 53.12 | 18.09 | 23.46 | 13.91 | 9.31 | 29.22 | 36.39 |
| Current ratioi | 8.50 | 7.08 | 7.06 | 5.43 | 4.99 | 3.34 | 3.63 | 3.56 |
| Quick ratioi | 8.12 | 6.80 | 6.68 | 5.18 | 4.70 | 3.13 | 3.41 | 3.32 |
| Debt / assetsi | 1.05 | 2.55 | 2.30 | 1.96 | 6.19 | 6.46 | 6.47 | 6.08 |
| LT debt / equityi | 0.95 | 2.85 | 2.61 | 2.32 | 7.64 | 8.39 | 8.50 | 8.01 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 184.26 | 71.62 | 29.71 | 18.89 | 18.52 | 22.83 | 14.76 | 12.93 |
| Net income CAGR (3Y) %i | -- | -- | -10.17 | -30.56 | -17.19 | 22.95 | 31.15 | 62.53 |
| FCF CAGR (3Y) %i | -- | 35.06 | 7.33 | -4.17 | -24.17 | -1.57 | 23.49 | 55.59 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 30.22 | 29.00 | 30.56 | 35.53 | 40.99 | 44.39 |
| ROA %i | 22.82 | 22.10 | 23.44 | 27.02 | 30.69 | 33.28 |
| ROIC %i | 25.17 | 23.98 | 25.84 | 30.40 | 35.19 | 38.25 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 35.43 | 33.71 | 35.85 | 38.48 | 40.29 | 40.72 |
| FCF / sales %i | 33.59 | 32.41 | 32.53 | 36.39 | 38.10 | 47.55 |
| Current ratioi | 3.50 | 3.51 | 3.75 | 3.56 | 3.26 | 3.46 |
| Quick ratioi | 3.29 | 3.22 | 3.47 | 3.32 | 2.98 | 3.21 |
| Debt / assetsi | 6.60 | 6.72 | 6.25 | 6.08 | 6.54 | 6.65 |
| LT debt / equityi | 8.78 | 8.84 | 8.17 | 8.01 | 8.76 | 9.00 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- CABOMETYX is the largest reported line at 90.77% of revenue, across 4 reported segments.
- The next-largest line, License revenues, is a distant second at 9.51% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
CABOMETYX90.77%
License revenues9.51%
COMETRIQ0.38%
Quote time 2026-10-08 08:26:00 · For reference only, not investment advice and not tailored to your situation.